BioSpace News Archive

Sentinel™ bedside urine output monitor for early detection and prevention of Acute Kidney Injury reduces patient risk

Relay Therapeutics, a new breed of company at the intersection of computation and biotechnology, announced the company’s expansion into genetic diseases and the appointment of James Nichols, Ph.D. as Head of Genetic Diseases.

Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended December 31, 2019.

Co-Diagnostics, Inc. (Nasdaq:CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that the GenomeWeb webinar scheduled to be delivered on February 5, 2020 will provide insight into work on the Company’s assay for the new strain of coronavirus,

Samsung Biologics, a pharmaceutical Contract Manufacturing Organization, recorded high for the fiscal year 2019, reporting 30.9% growth in sales at 701.6 billion won, and 64.6% growth in operating profit at 91.7 billion won compared to the previous year.

Demonstrating business momentum with FY2019 Q3 year-to-date (YTD) revenue 2,519.5 billion yen, up +82.6% versus prior year due to acquisition of Shire and continued strong performance of 14 global brands; while Underlying Revenue expected to recover in Q4 resulting in flat to slightly increasing for the full year

IRLAB has decided to use the name mesopedam for its drug candidate IRL790 following the recommendation for International Nonproprietary Name by the World Health Organization.

Hprobe announced the completion of a new funding round driven by international investors, providing an exceptional depth of expertise, a global ecosystem of partnerships and the endorsement of industry market leaders.

Centene Corporation announced its financial results for the fourth quarter and year ended December 31, 2019, reporting diluted earnings per share of $0.49 and $3.14, respectively, and Adjusted Diluted EPS of $0.73 and $4.42, respectively.

Axonics Modulation Technologies, Inc. announced that the German Institute for the Hospital Remuneration System granted Status 1 reimbursement approval to the Axonics r-SNM® System under a New Examination and Treatment Method.